Harold Edward Bays

12PUBLICATIONS
36CO-AUTHORS
PharmacogenomicsAboriginal and Torres Strait Islander sport and physical activityCancer therapy (excl. chemotherapy and radiation therapy)Behavioural epidemiologyCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 30, 2026
Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies.

|Apr 21, 2026
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.

|Jan 09, 2026
Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.

Harold E Bays, Phillip Toth, Naim Alkhouri

|Sep 07, 2025
Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAIN.

Deborah B Horn, Louis J Aronne, Sean Wharton

|Sep 03, 2025
Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4.

Theresa Hunter Gibble, Dachuang Cao, Madhumita Murphy

|Feb 08, 2025
Bempedoic Acid for Prevention of Cardiovascular Events in People With Obesity: A CLEAR Outcomes Subset Analysis.

Harold E Bays, LeAnne Bloedon, Danielle Brennan

Pageof 2

Frequent Collaborators

2 joint publications

Christie M Ballantyne

2 joint publications

Alberico L Catapano

2 joint publications

Anne Goldberg

2 joint publications

Kausik K Ray